Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27988942 | 0.87 | CYP2D6 (0.44) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| SCHEMBL3587080 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| SCHEMBL3639846 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| SCHEMBL3587507 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7462759 | 0.85 | CYP2D6 (0.51) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| SCHEMBL28159845 | 0.84 | CYP2D6 (0.50) | CYP2D6CYP1A2HTR6SMN1; SMN2KMT2A | |
| SCHEMBL14780313 | 0.83 | CYP2D6 (0.58) | CYP2D6CYP1A2GAASMN1; SMN2KMT2A | |
| SCHEMBL657896 | 0.83 | CYP2D6 (0.67) | CYP2D6CYP1A2GAAHTR6SMN1; SMN2 | |
| SCHEMBL11024375 | 0.83 | CYP2D6 (0.58) | CYP2D6CYP1A2GAASMN1; SMN2KMT2A | |
| SCHEMBL11024377 | 0.83 | CYP2D6 (0.58) | CYP2D6CYP1A2GAASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989164-A | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-110062761-B | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-113993868-A | Substituted pyrazolopyridinamides and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. | 2006-05-18 | — | — | US | disclosed |
| EP-1482944-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1482944-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003077855-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | CYP2D6 557/4885CYP1A2 444/4885GAA 3527/4885 |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | CYP2D6 507/4885CYP1A2 626/4885GAA 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.